I undertook my undergraduate medical training at the University of Sheffield, where I completed an intercalated BMedSci degree in pathology in 1995, and qualified in 1998. After completing Basic Surgical Training in South Yorkshire in 2003, I was awarded a Medical Research Council Fellowship (2004-2007) and undertook a PhD researching molecular mechanisms of prostate cancer progression. I then undertook higher surgical training in Urology in both Sheffield and Oxford, whilst in parallel continuing to pursue my prostate cancer research interests, leading to numerous scientific publications in this field under the mentorship of Professor Freddie Hamdy. In 2015, I was appointed Locum Consultant Urologist in Oxford and continued to combine clinical practice, specialising in the diagnosis and management of prostate cancer, with prostate cancer research. In 2017 I was appointed Honorary Consultant Urologist in Oxford.
Associate Professor of Urology
- Cancer Research UK / Royal College of Surgeons of England Clinician Scientist Fellow
- Honorary Urology Consultant
I am a Cancer Research UK Clinician Scientist Fellow (joint with the Royal College of Surgeons of England), which enables me to continue to combine my care of prostate cancer patients with a wide and growing prostate cancer research portfolio, covering the breadth of basic science, translational, and clinical research, at the Nuffield Department of Surgical Sciences.
I have been the Lead Clinician for the VANCE (VAcciNation in prostate CancEr) Clinical trial in Oxford since 2015, and in 2017 I commenced my current position as Honorary Consultant Urologist at the Churchill Hospital in Oxford.
I also deliver undergraduate teaching in surgery and urology to clinical medical students.
- Executive committee member of the Academic Section of the British Association of Urological Surgeons (BAUS) (2017-2019)
- Full member of BAUS, the European Urology Association (EAU), the Association of Academic European Urologists (AAEU), and the American Urology Association (AUA)
VANCE: First-in-human phase I study of a novel ChAdOx1-MVA 5T4 vaccine in low and intermediate risk prostate cancer
(2019), Journal of Clinical Oncology
Comparison of Multiparametric Magnetic Resonance Imaging and Targeted Biopsy With Systematic Biopsy Alone for the Diagnosis of Prostate Cancer: A Systematic Review and Meta-analysis.
Elwenspoek MMC. et al, (2019), JAMA Netw Open, 2
Testicular cancer in men with undescended testis: Insights from the Thames Valley Testicular Cancer database
(2019), Journal of Clinical Urology
Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy.
Wu X. et al, (2019), Prostate, 79, 1079 - 1089
Anti-androgens regulate amino acid-mTORC1 signalling and extracellular vesicle secretion to modulate prostate cancer progression
McCormick K. et al, (2019), CLINICAL & EXPERIMENTAL METASTASIS, 36, 167 - 167
Comparison of Prostate Biopsy with or without Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Detection: An Observational Cohort Study.
Bryant RJ. et al, (2019), J Urol, 201, 510 - 519